Enwave Corporation Stock
?
Your prediction
Enwave Corporation Stock
Pros and Cons of Enwave Corporation in the next few years
Pros
Cons
Performance of Enwave Corporation vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enwave Corporation | -2.440% | -4.762% | -0.621% | 10.345% | -32.203% | -44.444% | -82.456% |
| Aurinia Pharmaceuticals Inc. | - | 2.790% | 10.124% | 93.542% | 2.561% | 41.838% | 33.801% |
| Spectral Medical Inc | 0.600% | -1.183% | 0.602% | 71.107% | 5.031% | 332.642% | 133.240% |
| Xenon Pharmaceuticals Inc. | -2.110% | -4.435% | 1.282% | 42.771% | 24.737% | 40.237% | - |
News
EnWave Reports 2026 First Quarter Consolidated Interim Financial Results
Vancouver, B.C., February 20th, 2026. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the first
EnWave Signs Royalty-Bearing License with Bowen Gumlu Grower’s Association of Australia
Vancouver, B.C., February 2nd, 2026, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today announced that the Company has signed a royalty-bearing commercial license
EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results
Vancouver, B.C., December 15th, 2025 / EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the fourth

